Tristel Share Discussion Threads

[wad collector] 06/4/2024 19:27

Keep up the good work on the website Piedro ; it is appreciated.

[z1co] 25/3/2024 12:43

Buying a few sub £4.00 would be even better before the shares rerate to £5 - £6 plus.

[zimbtrader] 22/3/2024 14:32

Sliding daily... Excellent. Hopefully I can buy back the shares I sold at 477! Am thinking 420-430 would tempt me back.

[z1co] 11/3/2024 17:50

Another couple of delayed trades ( BUY'S ) of 200,000 @ £4.66 and 72,409 @ £4.675 from last Friday reported after the close today.

It's no surprise at all to these cheap shares being snapped up by buyer/s.

Will go ex. dividend in 10 days time for a very decent 5.24p

[z1co] 11/3/2024 15:47

The share price rise today is saying a lot of the stock sold after the results has already been bought by buyers.

[z1co] 08/3/2024 18:51

There were a total of 7 BUY trades of 50,000 and also another BUY of 218,160.As fast as someone is selling there's definitely a buyer/s picking up these cheap shares.

[z1co] 08/3/2024 16:24

Quite a few very large buy trades gone through this pm , buyer/s taking advantage.

[z1co] 08/3/2024 15:38

Yes the seller appeared on the 26/02/2024 hence no further rise in the share price.The seller will eventually finish , they always do and the shares will start climbing upwards again.

I'm tempted to buy more but i'm also waiting and watching and will hopefully pounce at the right time.

[74tom] 08/3/2024 13:11

Z1co, you won't often get a quote to buy 10k shares here because the EMS is 1500, although you can right now because there is clearly a seller around.

[piedro] 08/3/2024 07:45

Promoting in India

[z1co] 07/3/2024 11:18

A few large buys reported yesterday after the close 20,363 @ £4.75 being one of them.

No quote being given to buy 10,000 shares at the moment.

[z1co] 03/3/2024 13:34

"Conformity with MDR will allow us to apply CE marking to these new products and gives us the opportunity to deliver significant growth in sales of the Cache product range going forward.”

[z1co] 02/3/2024 09:18

(Alliance News) - Tristel PLC on Monday looked "positively" to the future, highlighting opportunities in the US after reporting a strong first half.

For the six months ended December 31, the Cambridgeshire, England-based infection prevention product manufacturer reported pretax profit of GBP3.4 million, up 44% from GBP2.4 million a year prior.

During the half, sales, general, and administrative expenses rose 27% to GBP11.9 million from GBP9.5 million. Tristel attributed this to a combination of inflationary increases and the recruitment of an additional 27 staff into its sales, marketing and distribution teams.

Revenue rose 20% to GBP20.9 million from GBP17.5 million. According to Tristel, higher sales volume accounted for GBP1.5 million of this growth, and price increases for the remaining GBP1.9 million.

The firm declared an interim dividend of 5.24 pence, doubled from 2.62p a year prior.

Pertinently, Tristel managed to secure in this period clearance from both the US Food & Drug Administration and Health Canada to sell Tristel ULT, its disinfectant foam. It plans to make a 510(K) submission to the FDA for this product during the summer, and expects clearance by the end of the year.

Separately on Monday, Tristel also said that reviews in the UK and the EU for approval of its TANK chlorine dioxide sporicidal disinfectant system have been successfully concluded, and a positive recommendation for UKCA and MDR certification has been made.

It expects to officially launch these latest products in Europe before the current financial year ends on June 30.

Looking forward, Tristel said that - with North America now "an active territory", and with further product approvals in the pipeline - the business is in "good shape".

[z1co] 28/2/2024 16:20

They will obviously develop new products , that's also a no brainer.

In the UK their products are being used in every hospital , that's some achievement.

Now they will do the same in the US and Canada.

[paulisi] 28/2/2024 16:07

It's a no brainer Growth was always going to happen once they got into US and Canada, their biggest market.No debt, high margin. Sitting on tons of cashNew product to be launched.At some stage there, will be a saturation point unless they develop more products

[z1co] 28/2/2024 15:43

The analysts are saying that the company will most likely double it's revenue and generate significantly higher profits and free flow cash over the next 5 years.

The share price will also achieve new highs , surpassing the previous highs of £7 set in 2021.

An excellent company that will also pay progressive dividends , making this a core holding for the long term.

[z1co] 28/2/2024 11:56

Tristel tipped to double revenue as it targets the North American market

By John Foster
26th February 2024

Tristel [LON:TSTL] the AIM-listed manufacturer of antibacterial cleaning products published its half-year results today (26th February). The Snailwell-based company specialises in infection prevention. Tristel develops products and solutions to help prevent the spread of harmful microbes, particularly in healthcare settings. Their main focus is on disinfecting medical devices and offers various products, like wipes and solutions, that healthcare professionals can use to disinfect reusable medical devices at the point of use, eliminating the need for sending them to a central sterilization department.

The firm also offers products for disinfecting surfaces including large surfaces like floors and walls and the company says that its products are formulated to be effective against a broad spectrum of microorganisms, including bacteria, viruses, and spores. Tristel’s technology utilizes a proprietary chlorine dioxide chemistry that they claim is unique in its effectiveness and safety compared to traditional disinfectants.

Back in July 2023 The Armchair Trader noted that Tristel was one on the UK’s top five performing healthcare stocks. In July it was trading at 360p, today Tristel opened at 499.6p climbing to 503.32p on release of its results, up 39.8%. Over one-year the share price is up 45.9% and up 73.6% over five-years.

The company saw its revenue grow 20% year-on-year to GBP20.9m in the six-months to the end of December 2023 with overseas sales up 13% to GBP12.7m and earnings up 21% to GBP4.7m

Tristel profits and dividends up

This led to reported profits before tax of GBP3.4m which were up y-o-y by 44% and the company doubled the interim dividend to 5.25p per share. The company has no debt and cash in the bank of GBP10.8m.

Paul Swinney, CEO, who announced his retirement at the end of the year, said in a statement this morning: “I am thrilled that the company continues to thrive and grow, with a pipeline of new product launches planned for the near term […] This six-month period represents the highest sales and profit performance that the company has experienced in its thirty-year history, including during the early COVID era when demand for our products was unprecedented.”

The company experienced strong growth in 2019-20 during the coronavirus pandemic, and as previously reported, was on the verge of entering the North American market, getting the greenlight from US and Canadian regulators to start marketing its products in the region. Sweeney said: “Our North American business strategy focuses on entering each of the key market segments that we dominate in other countries. Ultrasound is our largest segment globally in terms of disinfection procedure events, followed by ENT, cardiology and airway management. Ophthalmology is a very significant global opportunity in terms of disinfection events, but in all countries very few procedures that should be performed with a high-level disinfectant in fact are.”

The company is tipped to double its revenue in the next five years, with its North American strategy driving growth, and in the period reported saw the first manufacture and launch of Tristel ULT in the United States, a disinfection product that is used on ultrasound units, which also was cleared by regulators for distribution in Canada. The company already has clearance to sell its Tristel OHP product in Canada, a disinfectant for ophthalmic devices, and Tristel is in the process of submitting Tristel OHP to the US regulators.

North American manufacturing plant
The company has established a manufacturing facility in the United States, in New Jersey, with Parker Technologies and Swinney noted that during the first ten weeks of activity in North America, Tristel’s revenue and royalty was GBP46,000. He said: “We are very encouraged by this positive start.”

Bridgewise rates Tristel as ‘Outperform.’ The analyst said: “Tristel’s recent financial results position the company within the top 30% of Health Care firms. Specifically, EBITDA, Lease Adjusted and Return on Equity Ratio (ROE) overperformed relative to its peers. Analysing past performance, stronger relative performance in these metrics has often been associated with a higher likelihood of a company’s stock outperforming industry competitors. Taking into account Tristel’s recent financial performance, the company’s stock seems to offer a promising investment opportunity in the Health Care Equipment & Supplies industry.”

The simplicity and utility of Tristel’s products make regulatory clearance – often a high hurdle for other biotech companies – a great deal simpler, and the North American healthcare market is a vast and profitable market opportunity that could be transformational for the Cambridgeshire healthcare company.

[z1co] 27/2/2024 17:40

Yes we already know that 74tom.

Your post is a very subtle deramp suggesting that you have sold out and are waiting for a suitable re-entry.

Parker Laboratories plans an extensive marketing and trade show programme throughout 2024 and is in the process of expanding its salesforce in order to capitalise on the potential that Tristel ULT represents.

The company will provide more info regarding the US and Canadian revenue and the royalty TSTL will receive in their next trading update for the 6 months to June.

TSTL has always had a high rating even during and after the covid period when i last sold the shares.

The company has in 2024 entered a new phase of explosive growth which is likely to remain for many years.

[74tom] 27/2/2024 16:49

The company isn't selling directly into the US though is it Z1co, it's selling via Parker Labs & receiving a 24% royalty on net sales in return. The estimated TAM for ULT is $100m, so Parker need to capture a significant slice of this in order to make a material impact on their P&L.

Revenues in the first 10 weeks were £46k, assuming gross margins are similar to the UK and at around 87% that puts annualised sales at a run rate of around £1.1m gross to Parker, £240k to TSTL. They will need to penetrate around 30-40% of the TAM to get close to UK gross profit contribution, how long they will take to achieve that / whether it is possible appears key to whether there is attractive upside or whether this is actually pricing in too much future growth at a 34x PE ratio.

[z1co] 27/2/2024 13:37

It has taken the company more than 5 years to get an FDA approval for Tristel ULT and in June last year they managed to get this very important hurdle over the line.

The company achieved first sales in the US in November last year and sales will continue to increase throughout 2024 and subsequent years.

US is huge in comparison to the UK

[z1co] 27/2/2024 11:28

Clearance has been received from both the FDA last year and Health Canada in January 2024 to sell Tristel ULT,

In the US alone there are approximately 50m ultrasound scans which will generate up to $100m for Tristel/Parker with a net royalty of 24% for Tristel.

Going forward this is massive for Tristel and no wonder they have upped the interim dividend by 100%.

[z1co] 27/2/2024 10:43

Presentation via Investor Meet Company:

[z1co] 27/2/2024 09:28

Cavendish will have upgrade to it's 2023/24 forecasts substantially after the interim results today:

Was forecasting pre-tax profits of £7.6m and total dividend of 11.6p/share.

[z1co] 27/2/2024 09:24

The results were ahead of managements expectations even before US growth kicks in.

There will be a big increase in Cache sales in UK and Europe now that the Tank and Capsule certification imminent.

The management a very confident for the outlook hence they have increased the interim dividend by 100% to 5.24p.

[z1co] 27/2/2024 09:16

Bridgewise rates Tristel as ‘Outperform.’ The analyst said: “Tristel’;s recent financial results position the company within the top 30% of Health Care firms. Specifically, EBITDA, Lease Adjusted and Return on Equity Ratio (ROE) overperformed relative to its peers. Analysing past performance, stronger relative performance in these metrics has often been associated with a higher likelihood of a company’s stock outperforming industry competitors. Taking into account Tristel’s recent financial performance, the company’s stock seems to offer a promising investment opportunity in the Health Care Equipment & Supplies industry.”